PDS Biotechnology CorpPDSB
What PDS Biotechnology Corp does.
We are a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies
based on our Versamune® T cell activator and Versamune® in combination with our interleukin 12 (IL-12) fused anti-body drug conjugate (ADC), PDS01ADC. In addition, we are developing the Infectimune® T cell-activator in infectious diseases.
have the potential to overcome limitations of current immunotherapy approaches through effective conversion of the immune suppressive tumor to an immunogenic microenvironment in addition to the induction of the right type, potency and quantity of
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$14.8M | -$16.9M | -$40.9M | -$42.9M | -$37.6M | -$34.5M |
| Free cash flow | — | — | — | -$33.6M | -$35.1M | -$27.8M |
More on PDSB.
- PDS Biotechnology Corp summary
- PDS Biotechnology Corp financial statements
- PDS Biotechnology Corp key metrics
- PDS Biotechnology Corp health scores and style box
- PDS Biotechnology Corp earnings
- PDS Biotechnology Corp dividends
- PDS Biotechnology Corp valuation
- PDS Biotechnology Corp ownership and insiders
- PDS Biotechnology Corp peers
Figures from PDS Biotechnology Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.